COMP <GO>
BSX vs SYK // ALTMAN Z-SCORE & DEBT/EQUITY
Boston Scientific Corporation (NYSE) VS. Stryker Corporation (NYSE) • 15-METRIC TALLY: BSX 6
— SYK 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: SYK
LAST: $41.98 (-1.66%) • MKT CAP: $61.87B
balance-sheet
2.77
LAST: $291.86 (-6.38%) • MKT CAP: $119.58B
balance-sheet
4.46
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BSX VS. SYK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BSX | SYK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.00% | 64.00% | +5.00 | BSX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.20% | 11.60% | -2.40 | SYK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.8x | 23.6x | -7.80 | BSX | /valuation <GO> |
| Free Cash Flow Yield | 5.91% | 3.58% | +2.33 | BSX | /fcf-yield <GO> |
| Operating Margin | 18.00% | 19.50% | -1.50 | SYK | /operating-margins <GO> |
| Net Profit Margin | 14.00% | 12.90% | +1.10 | BSX | /net-margins <GO> |
| Revenue Growth (YoY) | 19.90% | 11.20% | +8.70 | BSX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.07% | -1.07 | SYK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 2.77 | 4.46 | -1.69 | SYK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | SYK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.0 | 59.4 | -16.40 | SYK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.13 | -0.14 | SYK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.5x | 34.2x | -15.70 | BSX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $61.87B | $119.58B | -$57.71B | SYK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BSX REV | SYK REV | BSX GROSS % | SYK GROSS % | BSX FCF | SYK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.07B | $25.12B | 69.0% | 64.0% | $3.66B | $4.28B |
| FY 2024 | $16.75B | $22.59B | 68.6% | 63.9% | $2.65B | $3.49B |
| FY 2023 | $14.24B | $20.50B | — | — | $1.86B | $2.79B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BSX // BETA 0.99
SYK // BETA 1.13